Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson(Harvard University), Kenneth C. Anderson(Dana-Farber Cancer Institute), Constantine S. Mitsiades(Dana-Farber Cancer Institute), Irene M. Ghobrial(Dana-Farber Cancer Institute), Sagar Lonial(Emory University), Sundar Jagannath(Mount Sinai Hospital), Robin Joyce(Beth Israel Deaconess Medical Center), Nikhil C. Munshi(Dana-Farber Cancer Institute), Carol Delaney(Beth Israel Deaconess Medical Center), Robert Knight(King's College London), Deborah Doss(Dana-Farber Cancer Institute), Noopur Raje(Massachusetts General Hospital), David Avigan(Beth Israel Deaconess Medical Center), Andrzej Jakubowiak(University of Chicago Medical Center), Wanling Xie(Dana-Farber Cancer Institute), Jonathan L. Kaufman(Emory University), Laura Lunde(Harvard University), Dixie‐Lee Esseltine(Millennium Engineering and Integration (United States)), Teru Hideshima(Harvard University), Amitabha Mazumder(NYU Langone Health), Robert Schlossman(University of Leeds), Diane Warren(Dana-Farber Cancer Institute), Edie Weller(Boston Children's Hospital), Sarah Kaster(Massachusetts General Hospital), David H. Vesole(Hackensack University Medical Center)
Cited by 866
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k